Lucid Diligence Brief: Surv BioPharma ¥670 million in Series B for primary malignant bone tumors
Lucid Diligence Brief: Surv BioPharma ¥670 million in Series B for primary…
Lucid Diligence Brief: Gilead licenses Assembly Bio’s HSV helicase-primase programs
Lucid Diligence Brief: Gilead licenses Assembly Bio’s HSV helicase-primase…
Lucid Diligence Brief: Vyriad $25M Series B to take in-vivo CAR-T into clinic
Lucid Diligence Brief: Vyriad $25M Series B to take in-vivo CAR-T into clinic…
Lucid Diligence Brief: Sanofi moves to buy Dynavax for $2.2B
Lucid Diligence Brief: Sanofi moves to buy Dynavax for $2.2B Professional…
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal Professional…
Lucid Diligence Brief: BioMarin to acquire Amicus Therapeutics for $4.8B
Lucid Diligence Brief: BioMarin to acquire Amicus Therapeutics for $4.8B…
Lucid Diligence Brief: Syremis Therapeutics launches with $165M Series A in schizophrenia
Lucid Diligence Brief: Syremis Therapeutics launches with $165M Series A in…
Lucid Diligence Brief: Sanofi and ADEL sign global licensing deal in Alzheimer's
Lucid Diligence Brief: Sanofi and ADEL sign global licensing deal in…
Lucid Diligence Brief: Impulse Dynamics $158m financing
Lucid Diligence Brief: Impulse Dynamics $158m financing Professional audiences…
Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity candidates
Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity……
Lucid Diligence Brief: Insilico-TaiGen CKD anemia licensing deal
Lucid Diligence Brief: Insilico-TaiGen CKD anemia licensing deal Professional…
Lucid Diligence Brief: Pfizer YaoPharma oral GLP-1 deal
Lucid Diligence Brief: Pfizer YaoPharma oral GLP-1 deal Professional audiences…